Author:
Hutton J. Thomas,Morris Jerry L.
Abstract
ABSTRACT:The safety and efficacy of Sinemet® CR, a controlled-release formulation of carbidopa/levodopa, were investigated in a three year, open-label trial involving 18 parkinsonian patients with fluctuating motor response. The average daily levodopa dosing frequency did not change significantly during long-term treatment. Efficacy measures generally revealed a gradual progression of parkinsonian disability. Patient diaries of motor fluctuations revealed relative stability of time “on” but with a tendency toward increased time “on with dyskinesias” over the 36 month followup period. There were no adverse laboratory results deemed to be related to Sinemet® CR and no unexpected side effects were observed.
Publisher
Cambridge University Press (CUP)
Subject
Clinical Neurology,Neurology,General Medicine
Reference32 articles.
1. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson’s disease;Hutton;Neurology,1989
2. Long-term clinical efficacy of Sinemet CR in patients with Parkinson’s disease;Rodnitzky;Neurology,1989
3. Comparison of Controlled-Release Sinemet (CR4) and Standard Sinemet (25 mg/100 mg) in Advanced Parkinsonʼs Disease
4. ON-OFF FLUCTUATIONS IN PARKINSON'S DISEASE
5. the treatment of patients with Parkinson’s disease already on long-term treatment with levodopa;Aarli;Neurology,1989
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献